Advertisement

Pharmacy Implications

  • Stacey AlbuquerqueEmail author
Chapter

Abstract

The immunocompromised patient may be admitted to the ICU as a consequence of a new diagnosis, treatment-related toxicity, or disease progression. The pharmacologic management of the critically ill immunocompromised child in the pediatric intensive care unit (PICU) brings forth a unique set of challenges as these patients are often prone to medication toxicity due to their organ compromise and increased potential for the development of drug interactions due to the amount of medications that may be utilized to treat evolving conditions. In addition to understanding the immunologic or oncologic processes of these patients, knowledge and understanding drug disposition and drug interactions are necessary to maximize efficacy of treatment and minimize medication-induced toxicity where possible.

Keywords

Immunocompromised Pharmacology drug disposition Drug interactions Toxicity 

References

  1. 1.
    Besunder JB, Pope J. Pharmacology in the PICU. In: Wheeler DS, Wong H, Shanley P, editors. Critical care medicine. London: Spriger; 2014. p. 55–73.CrossRefGoogle Scholar
  2. 2.
    Reed MR, Blumer J. Therapeutic drug monitoring in the pediatric intensive care unit. Pediatr Clin N Am. 1994;41:1227–43.CrossRefGoogle Scholar
  3. 3.
    Zuppa AF, Barrett JS. Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr Clin N Am. 2008;55:735–55.CrossRefGoogle Scholar
  4. 4.
    Shimabukuro-Vornhagen AS, Boll B, Kochanek M, et al. Critical care of patients with cancer. CA Cancer J Clinic. 2016;66:496–517.CrossRefGoogle Scholar
  5. 5.
    Benton WW, Brothers AW, Jefferis Kirk CC, et al. Adverse drug reactions and drug-drug interactions. In: Fuhrman BP, Zimmerman JJ, editors. Pediatric critical care. Philadelphia: Elsevier; 2011. p. 1569–89.CrossRefGoogle Scholar
  6. 6.
    Benoit DD, Hoste E. Acute kidney injury in patients with cancer. Crit Care Clin. 2010;26:151–79.CrossRefGoogle Scholar
  7. 7.
    Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet. 1988;14:347–73.CrossRefGoogle Scholar
  8. 8.
    Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 2003;29:280–4.CrossRefGoogle Scholar
  9. 9.
    Blower P, deWit R, Goodin S. Drug-drug interactions in oncology: why are they important and how can they be minimized. Crit Rev Oncol Hematol. 2005;55:117–42.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing 2019

Authors and Affiliations

  1. 1.Boston Children’s Pharmacy DepartmentDana Farber/Boston Children’s Cancer and Blood Disorders CenterBostonUSA

Personalised recommendations